Comparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis
- سال انتشار: 1398
- محل انتشار: مجله تحقیقات دارویی و بیومدیک، دوره: 5، شماره: 4
- کد COI اختصاصی: JR_PBRE-5-4_002
- زبان مقاله: انگلیسی
- تعداد مشاهده: 248
نویسندگان
Sina MS Research Center, Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sina MS Research Center, Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sina MS Research Center, Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sina MS Research Center, Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sina MS Research Center, Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Bio Statistician Research Institute, Baylor Scott & White Health, Dallas, Texas, United States of America.
Department of Clinical Pharmacy, Faculty of pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
چکیده
Background: The present study aimed to compare the clinical efficacy and safety profile of Ziferon and Betaferon. Objectives: In total, ۴۱ consecutive patients with relapsing forms of Multiple Sclerosis (MS) were selected from the MS outpatient clinic affiliated to Tehran University of Medical Sciences. The patients were randomly assigned into two groups. Methods: Each group either received Ziferon ۲۵۰ mcg Subcutaneously (SC) in alternate days or Betaferon ۲۵۰ mcg SC on alternate days. Clinical and para-clinical outcomes, such as mean relapse rate/year score, mean Expanded Disability Status Scale (EDSS)/year score, the cumulative number, and the volume of gadolinium-enhancing lesions, in addition to the cumulative number of new T۲ lesions and safety profile were evaluated for each group during the years of treatment. Results: There were no significant differences in Magnetic Resonance Imaging (MRI) outcomes (change in total lesion volume, new lesion per T۲-weighted scan, and gadolinium-enhancing lesions per T۱-weighted scan from baseline; P=۰.۲۳۶, P=۰.۵۶, & P=۰.۴۹۶, respectively was observed). There was no significant difference in the relapse rate between Ziferon and Betaferon treated groups (P=۰.۵۶). There were no unexpected safety events. The number of patients who discontinued the study due to adverse events occurrence was similar between the two groups. Conclusion: Evidence demonstrates the non-inferiority and bio-similarity of Ziferon (interferon beta-۱b) to Betaferon in terms of efficacy and safety profile.کلیدواژه ها
Interferon-beta (INF-β)۱b, Relapsing-Remitting Multiple Sclerosis (RRMS), Outcome measureاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.